Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals

Brain, Behavior, and Immunity

Volumn 25, Issue 7, 2011, Pages 1460-1467

  Agliardi, Cristina ^a   Guerini, Franca R ^a   Saresella, Marina ^a   Caputo, Domenico ^a   Leone, Maurizio A ^b   Zanzottera, Milena ^a   Bolognesi, Elisabetta ^a   Marventano, Ivana ^a   Barizzone, Nadia ^c   Fasano, Maria E ^d   Al Daghri, Nasser ^e   Clerici, Mario ^a,f  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Genetic susceptibility; HLA DRB1*15; Multiple sclerosis; SNP; VDR; Vitamin d

Indexed keywords

HLA DR ANTIGEN; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; ALLELE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 80052771713     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.05.015     Document Type: Article

References (44)

1. Acheson E.D. Epidemiology of multiple sclerosis. Br. Med. Bull. 1977, 33(1):9-14.
2. Acheson E.D., Bachrach C.A., Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiat. Scand. Suppl. 1960, 35(147):132-147.
3. Alter M., Kahana E., Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978, 28(11):1089-1093.
4. Arai H., Miyamoto K., Taketani Y., Yamamoto H., Iemori Y., Morita K., Tonai T., Nishisho T., Mori S., Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 1997, 12(6):915-921.
5. Berer A., Stockl J., Majdic O., Wagner T., Kollars M., Lechner K., Geissler K., Oehler L. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and migration in vitro. Exp. Hematol. 2000, 28:575-583.
6. Cantorna M.T., Hayes C.E., De Luca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93(15):7861-7864.
7. Colin E.M., Weel A.E., Uitterlinden A.G., Buurman C.J., Birkenhager J.C., Pols H.A., van Leeuwen J.P. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin. Endocrinol. (Oxf.) 2000, 52(2):211-216.
8. Dean G., Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1997, 63(5):565-568.
9. Dickinson J.L., Perera D.I., van der Mei A.F., Ponsonby A.L., Polanowski A.M., Thomson R.J., Taylor B.V., McKay J.D., Stankovich J., Dwyer T. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult. Scler. 2009, 15(5):563-570.
10. Feldman D., Glorieux F.H., Pike J.W. Vitamin D 2005, London Academic press, San Diego.
11. GAMES Transatlantic multiple sclerosis genetics cooperative. A meta-analysis of whole genome linkage screens in multiple sclerosis. J. Neuroimmunol. 2003, 143(1-2):39-46.
12. Goldberg P., Fleming M.C., Picard E.H. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses 1986, 21(2):193-200.
13. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98(12):6800-68055.
14. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., Oksenberg J.R., Lincoln R., Zhang D.Y., Banatao D.R., Gatto N., Goodkin D.E., Hauser S.L. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum. Mol. Genet. 1998, 7(8):1229-1234.
15. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet 1972, 1(7762):1240-1241.
16. Kidd L.C., Paltoo D.N., Wang S., Chen W., Akereyeni F., Isaacs W., Ahaghotu C., Kittles R. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 2005, 64(3):272-282.
17. Kimball S.M., Ursell M.R., O'Connor P., Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007, 86(3):645-651.
18. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Bäckström B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., Oukka M., Kuchroo K. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 2007, 13:423-431.
19. Kurtzke J.F., Hyllested K., Arbuckle J.D., Brønnum-Hansen H., Wallin M.T., Heltberg A., Jacobsen H., Olsen A., Eriksen L.S. Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurol. Scand. 1997, 96(3):149-157.
20. Larsen J.P., Riise T., Nyland H., Kvale G., Aarli J.A. Clustering of multiple sclerosis in the county of Hordaland, Western Norway. Acta Neurol. Scand. 1985, 71(5):390-395.
21. Lemire J.M., Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 1991, 87(3):1103-1107.
22. Li Z., Zhang Z., He Z., Tang W., Li T., Zeng Z., He L., Shi Y.Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. Cell Res. 2009, 19(4):519-523. (http://analysis.bio-x.cn).
23. Marshall T.G. Are statins analogues of vitamin D?. Lancet 2006, 368(9543):1234.
24. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
25. Morrison N.A., Qi J.C., Tokita A., Kelly P.J., Crofts L., Nguyen T.V., Sambrook P.N., Eisman J.A. Prediction of bone density from vitamin D receptor alleles. Nature 1994, 367:284-287.
26. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296(23):2832-2838.
27. Nataf S., Garcion E., Darcy F., Chabannes D., Muller J.Y., Brachet P. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 1996, 55(8):904-914.
28. Nejentsev S., Godfrey L., Snook H., Rance H., Nutland S., Walker N.M., Lam A.C., Guja C., Ionescu-Tirgoviste C., Undlien D.E., Rønningen K.S., Tuomilehto-Wolf E., Tuomilehto J., Newport M.J., Clayton D.G., Todd J.A. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum. Mol. Genet. 2004, 13(15):1633-1639.
29. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994, 44(9):1687-1692.
30. Norman A.W. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am. J. Clin. Nutr. 1998, 67(6):1108-1110.
31. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991, 38(1):1-15.
32. Opsahl M.L., Kennedy P.G.E. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 2005, 128:516-527.
33. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30(9):e36.
34. Prüfer K., Barsony J. Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor. Mol. Endocrinol. 2002, 16(8):1738-1751.
35. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., Deluca G.C., Herrera B.M., Chao M.J., Sadovnick A.D., Ebers G.C., Knight J.C. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009, 5(2):e1000369.
36. Saresella M., Marventano I., Guerini F.R., Zanzottera M., Delbue S., Marchioni E., Maserati R., Longhi R., Ferrante P., Clerici M. Myelin basic protein-specific T lymphocytes proliferation and programmed cell death in demyelinating diseases. Clin. Immunol. 2008, 129(3):509-517.
37. Saresella M., Marventano I., Longhi R., Dissoni F., Trabattoni D., Mendozzi L., Caputo D., Clerici M. CD4+CD25+FoxP3+PD1-regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008, 22:3500-3508.
38. Sato F., Tanaka H., Hasanovic F., Tsunoda I. Theiler's virus infection: pathophysiology of demyelination and neurodegeneration. Pathophysiology 2011, 18(1):31-41.
39. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15(2):97-98.
40. Smolders J., Damoiseaux J., Menheere P., Tervaert J.W., Hupperts R. Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis. Ann. NY Acad. Sci. 2009, 1173:515-520.
41. Towers T.L., Staeva T.P., Freedman L.P. A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Mol. Cell. Biol. 1999, 19(6):4191-4199.
42. Uitterlinden A.G., Fang Y., Van Meurs J.B., Pols H.A., Van Leeuween J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338(2):143-156.
43. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
44. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagay Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19(11):2685-2695.